Robert Lofberg

Plain English
This study looked at how the length of time a person has Crohn's Disease affects their response to the medication adalimumab. Researchers found that patients who started treatment within the first year of being diagnosed had the best results; 45.8% of these patients achieved remission compared to 31.0% for those diagnosed between one and two years, and only 23.1% and 23.6% for those diagnosed two to five years, and more than five years ago, respectively. This is important because starting treatment earlier can lead to better long-term health outcomes for patients. Who this helps: Patients newly diagnosed with Crohn's Disease.

Plain English
This study looked at how the medication adalimumab affects extraintestinal symptoms in patients with Crohn's disease, such as joint pain and skin issues. Researchers found that after 6 months, 54% of patients on adalimumab saw improvement in these symptoms compared to 31% of those on a placebo. After a year, 60% of those on adalimumab improved, while 42% on the placebo did. This is important because it shows that adalimumab is a useful treatment for alleviating these additional health problems related to Crohn's disease. Who this helps: This helps patients with Crohn's disease who experience extraintestinal symptoms.

Plain English
This study looked at how effective and safe infliximab, a treatment for chronic active ulcerative colitis, is over a long period for 250 patients. Researchers found that nearly half of the patients (49.2%) achieved remission after one year, and 76% responded to the treatment within three months, with a risk of needing surgery to remove part of the colon significantly higher for those who did not respond initially (48.3%). This research matters because it helps identify which patients are likely to benefit from infliximab and highlights the importance of early response to treatment to avoid severe complications. Who this helps: This helps patients with chronic active ulcerative colitis and their doctors in deciding treatment options.

Plain English
This study looked at the genetic factors that might increase the risk of collagenous colitis (CC), a condition that causes chronic diarrhea, especially in older women. Researchers found that certain genetic variants, particularly in the HLA region of the genome, were strongly linked to a higher risk of developing CC. Specifically, they identified that the DQ2.5 variant was associated with about double the risk of the disease (odds ratio of 2.06). Understanding these genetic links helps clarify the role that the immune system plays in CC. Who this helps: This benefits patients with collagenous colitis and their doctors by providing insights into the genetic risks involved.

Plain English
This study looked at how effective low-dose budesonide is for keeping patients with collagenous colitis symptom-free over a year. It found that 61.4% of those on budesonide maintained remission compared to just 16.7% of those on a placebo, a significant difference of 44.5%. This matters because it shows that budesonide can help many patients stay healthy and maintain a good quality of life without serious side effects. Who this helps: This helps patients with collagenous colitis.

Plain English
This study looked at 795 patients with microscopic colitis, which causes chronic diarrhea, and found that 57% had lymphocytic colitis (LC) while 43% had collagenous colitis (CC). The average age for a CC diagnosis was 63 years, while for LC it was 59 years, and CC patients reported more severe symptoms, like watery diarrhea in 55% compared to 43% of LC patients. This matters because understanding the differences between CC and LC can help doctors provide better care for patients with these conditions. Who this helps: This benefits patients suffering from chronic diarrhea due to microscopic colitis and their doctors.

Plain English
This study looked at how often patients with inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC), used healthcare services and what treatments they received. Out of nearly 14,000 patients, about 49% were prescribed medication for their condition, with 32.4% receiving aminosalicylates and 9.6% receiving biological treatments; in comparison, only 3.6% were given high-dose corticosteroids. The findings show that patients with Crohn’s disease required more outpatient visits, hospitalizations, and surgeries than those with ulcerative colitis, indicating that they have greater medical needs. Who this helps: This research helps patients with Crohn’s disease and their healthcare providers understand the challenges they face and the treatment options available.

Plain English
This study looked at how many Swedish patients with inflammatory bowel disease (IBD) use complementary and alternative medicine (CAM) compared to a control group. It found that 48.3% of IBD patients used CAM in the past year, while 53.5% of the control group did, with massage being the most popular form among IBD patients (21.3%). Most patients (83.1%) reported feeling positive effects from CAM, which is important because many patients also experience side effects from standard treatments. Who this helps: This helps patients with IBD who seek additional options for managing their condition.

Plain English
This study investigated the effects of a new treatment called DIMS0150, which is applied directly to the inside of the intestines, in patients with moderate to severe ulcerative colitis who had not responded to standard treatments. The researchers found that while DIMS0150 did not significantly increase the overall rate of clinical remission at 12 weeks (44.4% for DIMS0150 compared to 46.5% for the placebo), it did lead to more symptom relief and mucosal healing earlier on; 32.1% of patients on DIMS0150 reported less severe symptoms by week 4, compared to only 14.0% of those on placebo. This treatment appears safe and could provide a new option for patients struggling with this challenging condition. Who this helps: This helps patients with chronic ulcerative colitis who haven't found relief with traditional treatments.

Plain English
This study looked at how certain biological markers can predict which ulcerative colitis patients who do not respond to steroids are likely to benefit from a new treatment called DIMS0150. The researchers found that out of 34 patients tested, the markers predicted a good response to DIMS0150 in over 90% of the cases. This is important because it can help doctors personalize treatment plans for patients who struggle with their current medications. Who this helps: This helps patients with ulcerative colitis who do not respond to standard steroid treatments.

Plain English
This study looked at how well the medication adalimumab works for people with moderate to severe Crohn's disease. Researchers found that after 20 weeks of treatment, 60% of patients who hadn’t used another similar drug before improved their quality of life significantly, and they also experienced an average savings of around €3,070 in lost work productivity. These findings are important because they show that adalimumab not only helps patients feel better but also saves them money by allowing them to work more effectively. Who this helps: This research benefits patients with Crohn's disease, especially those who have not responded to other treatments.

Plain English
This research studied a treatment called DIMS0150 for patients with chronic active ulcerative colitis (UC) who were facing surgery to remove their colon. After administering DIMS0150 to eight patients, 71% showed improvement within a week, and by 12 weeks, 82% had responded to treatment, with 71% achieving remission. Most patients avoided surgery for over two years, with one remaining symptom-free for more than 27 months. Who this helps: This helps patients with chronic active ulcerative colitis seeking alternatives to surgery.

Plain English
This study looked at how a local anesthetic called ropivacaine affects rectal function in patients with ulcerative colitis, particularly those experiencing inflammation. Researchers tested seven patients with active disease and compared their results to seven healthy individuals. They found that patients with active colitis felt the need to use the bathroom at lower volumes and had increased sensitivity and responsiveness in their rectum, which is linked to inflammation. However, the use of ropivacaine did not improve these issues, meaning that while patients might feel better, the underlying problems with rectal function remain unchanged. Who this helps: This research helps patients with ulcerative colitis and their doctors understand the limitations of current treatments for symptoms related to rectal function.

Plain English
This study looked at how effective the drug adalimumab is for treating people with moderate to severe Crohn's disease, especially in reducing related health issues outside of the intestines. Of the 945 patients studied, 52% achieved clinical remission after 20 weeks, and among those who had never been treated with another drug (infliximab), the remission rate was even higher at 62%. Additionally, more than half of the patients with extraintestinal problems reported no symptoms after the same period, indicating adalimumab not only helps with Crohn's itself but also other associated conditions. Who this helps: This research benefits Crohn's disease patients and their doctors by providing evidence of the effectiveness of adalimumab.

Plain English
This study looked at how a specific treatment called leukocyte apheresis affects certain proteins in patients with inflammatory bowel disease (IBD). Researchers found that during the treatment, a substance called soluble IL-1 receptor type I (sIL-1RI) was significantly produced, suggesting that this process might help reduce inflammation. Understanding these changes can improve future treatment designs and how we study these therapies. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

Plain English
This study examined how DNA changes and abnormal tissue growth (called dysplasia) in patients with Crohn's disease could indicate a higher risk of developing colorectal cancer. Researchers followed 245 patients over about 9 years and found that 22% had DNA aneuploidy, and 17% had dysplasia. Those with DNA aneuploidy were 5.3 times more likely to have dysplasia, and those with dysplasia had a 10 times higher chance of developing colorectal cancer. Who this helps: This research helps patients with Crohn's disease and their doctors understand the risks of colorectal cancer better.

Plain English
This research focused on when and how to use biological therapies for patients with inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. It found that infliximab is the most studied treatment, but others like adalimumab and certolizumab are also effective. Notably, about one-third of patients who have been in remission for over a year may stay well even after stopping treatment. Who this helps: This information benefits patients with inflammatory bowel disease and their doctors, helping them make better treatment decisions.

Plain English
This research looks at a treatment called granulocyte/monocyte adsorption (GMA) using the Adacolumn for patients with inflammatory bowel disease (IBD). The study found that GMA not only removes certain harmful white blood cells, but also promotes the release of beneficial anti-inflammatory substances, while increasing helpful lymphocytes. This approach shows promise for improving treatment outcomes for IBD patients and has a strong safety record. Who this helps: This helps patients with inflammatory bowel disease.

Plain English
This study tested a treatment called recombinant cholera toxin B subunit on 15 patients with Crohn's disease to see if it was safe and effective. The treatment showed that about 40% of patients experienced a significant improvement in their symptoms within weeks, and around 30% were in remission after eight weeks. This matters because finding new treatment options for Crohn's disease can help improve the quality of life for many patients suffering from this chronic condition. Who this helps: Patients with Crohn's disease.

Plain English
This study looked at how inflammatory bowel disease (IBD) affects the risk of colorectal cancer (CRC) in men and women. The researchers found that men with IBD had a 60% higher risk of developing CRC compared to women, with cumulative rates showing 8.3% for men and 3.5% for women after 40 years. This is important because it highlights the need for different cancer monitoring strategies based on sex for patients with IBD. Who this helps: This helps doctors and health care providers in managing the cancer screening and treatment of patients with IBD.

Plain English
This study looked at the presence of specific DNA markers, called DNA adducts, in the colon tissues of healthy individuals, patients with polyps, and those with colon cancer. Researchers found no significant differences overall in the levels of DNA adducts among the groups, but identified that certain DNA adducts were lower in the normal tissue next to tumors and one type was only found in cancer tissues. These findings matter because they suggest that some DNA adducts might be useful in tracking the development of colon cancer. Who this helps: This helps patients and doctors in understanding potential markers for colon cancer progression.

Plain English
This study tested a new medical device called Cellsorba EX for treating people with ulcerative colitis, a condition that causes inflammation in the intestines. In a trial with six patients, the device was found to be safe, with no serious side effects, and it reduced the severity of symptoms—patients' Mayo scores, which measure disease activity, dropped from an average of 8.0 to 3.5 in eight weeks. Four patients showed significant improvement, with two going into remission. Who this helps: This benefits patients with ulcerative colitis who are looking for effective treatments when standard medications are not enough.

Plain English
This study looked at how the risk and death rates from colorectal cancer (CRC) have changed for patients with inflammatory bowel disease (IBD) over several decades. It found that while the number of new CRC cases among these patients has not significantly decreased, the death rate from CRC has dropped dramatically, particularly since the 1960s—by several times. This matters because it shows that improvements in the way IBD is managed are helping patients live longer lives, even if the risk of getting CRC remains steady. Who this helps: This benefits patients with inflammatory bowel disease.

Plain English
This study looked at a specific gene, IL23R, in different populations to see if it is linked to inflammatory bowel disease (IBD), psoriasis, and celiac disease. Researchers confirmed that IL23R is associated with IBD in Swedish patients, while in Finnish patients, they found links between IL23R and both psoriasis and celiac disease. This research is important because it highlights how genetic factors can play a role in chronic inflammatory diseases and may help improve understanding and treatment options for these conditions. Who this helps: This research benefits patients with inflammatory bowel disease, psoriasis, and celiac disease.

Plain English
This study looked at genetic variations in the SLC15A1 gene, which is involved in transporting substances in the gut, to see how they relate to inflammatory bowel diseases (IBD) like Crohn's disease (CD) and ulcerative colitis (UC). Researchers analyzed 1783 individuals from Sweden and Finland and found that a specific genetic variant (rs2297322) was linked to an increased risk of CD in Sweden (almost double the risk) but provided protection in Finland. These findings highlight the importance of understanding genetic differences in IBD, which could help personalize treatments. Who this helps: This helps patients with inflammatory bowel disease by clarifying potential genetic factors affecting their condition.

Plain English
This study examined the effects of a treatment called selective leukocyte apheresis (GCAP) on patients with active inflammatory bowel disease (IBD). After five treatment sessions, researchers found that substantial decreases in certain immune cells (specifically, FoxP3-positive and TLR-2-positive cells) were linked to improvements in the patients' symptoms; for example, the decrease in FoxP3-positive cells had a significance level of P = 0.012 and TLR-2-positive cells at P = 0.008. This is important because it highlights a potential connection between these immune cells and the disease process, suggesting that reducing their numbers can help patients feel better. Who this helps: This helps patients with inflammatory bowel disease seeking better treatment options.

Plain English
This study looked at how certain genes can help doctors tell the difference between ulcerative colitis, Crohn's disease, and irritable bowel syndrome, which can share similar symptoms. Researchers found seven specific genes that were expressed differently in patients with these conditions, allowing for a highly accurate diagnosis with an accuracy ranging from 91.5% to 99.9%. This is important because a correct diagnosis can lead to better treatment and management of these gastrointestinal disorders. Who this helps: This benefits patients suffering from digestive issues by ensuring they receive the right diagnosis and treatment.

Plain English
This study examined how patients with ulcerative colitis (UC) respond to steroid treatment by looking at certain proteins in their colorectal tissue. Researchers found that patients who responded well to steroids had higher levels of glucocorticoid receptors (GR) after one week of treatment compared to those who didn't respond; specifically, responders had a 39% increase in GR levels. This discovery is important because it helps explain why some patients don't benefit from steroids, which could improve treatment strategies for better outcomes. Who this helps: This helps patients with ulcerative colitis and their doctors by identifying who may benefit from steroid treatments.

Plain English
This study looked at a treatment called granulocyte/monocyte apheresis for patients with moderate-to-severe ulcerative colitis, a serious gut disease. Out of 168 participants in the main trial, 17% treated with the apheresis reached clinical remission compared to 11% with a sham treatment, showing no significant difference. The treatment was safe but did not effectively induce clinical remission or improve symptoms compared to the sham procedure. Who this helps: This research is relevant for patients with ulcerative colitis and their doctors looking for new treatment options.

Plain English
This study looked at gene activity in the intestines of patients with ulcerative colitis (UC), a type of inflammatory bowel disease. Researchers found 331 genes that were expressed differently in UC compared to Crohn's disease, with a newly identified gene called WAFL being particularly noteworthy, as it was linked to the immune response and not present in Crohn's patients. Understanding WAFL could lead to better ways to diagnose and treat UC, as it offers insight into the mechanisms of this condition. Who this helps: This research benefits patients with ulcerative colitis by paving the way for more targeted treatments.

Plain English
This study looked at how a group support program for patients with inflammatory bowel disease (IBD) affected their quality of life and coping skills. Researchers found that, on average, patients did not experience significant changes in their overall quality of life scores after participating in the program, with scores remaining around 175, but the program was well-received by participants. Notably, those with a shorter disease duration showed some improvement in their quality of life. Who this helps: This helps IBD patients, especially those who are newly diagnosed.

Plain English
Researchers studied a new treatment called granulocyte, monocyte/macrophage apheresis for patients with inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Of the first 100 patients treated, 48% with ulcerative colitis and 41% with Crohn's disease experienced clinical remission, and a significant number were able to stop using steroids. This matters because it offers a promising option for patients who do not respond to traditional medications, with low risks of severe side effects. Who this helps: This helps patients with ulcerative colitis and Crohn's disease who struggle to control their symptoms.

Plain English
This study examined a treatment called granulocyte and monocyte adsorption (GMA) for people with inflammatory bowel disease (IBD). Researchers found that GMA significantly reduced harmful immune cells and led to an increase in beneficial immune cells, which helps to control inflammation. This treatment may provide a safer alternative to traditional drugs, potentially reducing the need for steroids and other medications that can have negative side effects. Who this helps: This helps patients with inflammatory bowel disease looking for safer treatment options.

Plain English
This study looked at a specific gene called NPSR1 to see if variations in it are linked to inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. Researchers found a significant connection between certain genetic variations and IBD; for example, one variation increased the risk of Crohn's disease by 0.05% and another offered some protection against ulcerative colitis. These findings are important because identifying genetic risk factors could help doctors predict who might develop IBD and tailor treatments accordingly. Who this helps: Patients at risk for inflammatory bowel disease and their healthcare providers.

Plain English
This study looked at genetic factors that might make people more likely to develop Crohn's disease in Sweden. Researchers compared 178 patients with Crohn's disease to 143 healthy people and found that certain gene variants were linked to the disease. Specifically, they found that people with the IGR2096a_1 marker had a 55% higher risk of Crohn's disease compared to healthy individuals, and variants of the genes SLC22A4 and SLC22A5 also showed significant associations. Who this helps: This research helps patients with Crohn's disease and their doctors by improving understanding of genetic risks associated with the condition.

Plain English
This study looked at the common DeltaF508 mutation in cystic fibrosis to see if it plays a role in Crohn's disease, a type of inflammatory bowel disease. Researchers analyzed 2,568 people from Italy, Sweden, and Scotland and found that people with this mutation were less likely to have Crohn's disease, especially in Italian and Swedish patients. This matters because it suggests that the DeltaF508 mutation might help protect against Crohn's disease, which could influence future research and treatment options. Who this helps: Patients with Crohn's disease and healthcare providers.

Plain English
This study looked at a treatment called leukocyte apheresis for patients with inflammatory bowel diseases like Crohn's disease and ulcerative colitis, who were not improving with standard medications. Over 12 months, patients who received the treatment showed a significant drop in their disease activity scores, decreasing from 12 to 4, and five patients were in remission after a year. The treatment also lowered levels of a specific immune marker called interferon-gamma, which may help predict long-term improvements in patients' conditions. Who this helps: This helps patients with inflammatory bowel diseases who do not respond to conventional treatments.

Plain English
This study looked at the presence of citrullinated proteins, which are linked to inflammation, in various tissues from patients with inflammatory conditions and healthy individuals. Researchers found that all samples from patients with rheumatoid arthritis and myositis had high levels of citrullination, while only a few healthy samples had it. This finding shows that citrullination occurs in response to inflammation itself, not just specific diseases, implying it could be an important marker for diagnosing inflammatory conditions. Who this helps: This helps patients with inflammatory diseases and doctors diagnosing these conditions.

Plain English
This study looked at how specific genetic changes in the CARD15 gene relate to Crohn's disease in Swedish patients. It found that two variants, R702W and G908R, were more common in people with Crohn's disease (4.5% and 2.0% respectively) compared to healthy individuals (0.7% and 0%). These variants seem to make patients more likely to develop ileal Crohn's disease, which affects the last part of the small intestine, while offering some protection against a form of the disease that affects the colon. Who this helps: This helps patients with Crohn's disease understand the genetic factors that may contribute to their condition.

Plain English
This study looked at how often DNA changes linked to cancer occur in patients with colon Crohn's disease who also have colorectal cancer (CRC). They found that 62.5% of CRC tumors in these patients had DNA abnormalities, and these changes were also present in some nearby tissues. The findings show that monitoring for these DNA changes could help identify patients at higher risk for developing cancer, improving their chances for early detection and treatment. Who this helps: This research benefits patients with colon Crohn's disease by improving cancer screening and monitoring strategies.

Plain English
Researchers studied a new treatment method called granulocyte apheresis for patients with ulcerative colitis who didn't respond to steroids. Out of 35 patients analyzed, 37.1% entered clinical remission, meaning their symptoms significantly improved, and 28.6% showed improvement in endoscopic results. Moreover, patients reported a notable increase in their quality of life after treatment. This is important because it offers a potential new option for patients struggling with this severe condition when standard treatments fail. Who this helps: This helps patients with steroid-resistant ulcerative colitis.

Plain English
This study looked at the cost-effectiveness of using budesonide controlled ileal release (CIR) capsules for maintaining treatment in patients with ileocaecal Crohn's disease compared to not using any maintenance therapy. It found that patients using the capsules experienced about 16.6 fewer days of relapse over a year, which translates to a 6% increase in days spent in remission. While treatment costs increased by around 1,673 SEK (or about $220), the overall benefits, including fewer hospital visits and better patient quality of life, make this maintenance therapy a cost-effective option. Who this helps: This research helps patients with Crohn's disease by providing them with a potentially better quality of life through effective management of their condition.